These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report. Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829 [TBL] [Abstract][Full Text] [Related]
23. Verrucous papillomatous lesion of post-kala-azar dermal leishmaniasis: fine needle aspiration diagnosis of an unusual presentation. Bhadani PP; Sen R; Singh RK Acta Cytol; 2007; 51(2):252-4. PubMed ID: 17425218 [No Abstract] [Full Text] [Related]
24. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Gilad J; Borer A; Hallel-Halevy D; Riesenberg K; Alkan M; Schlaeffer F Isr Med Assoc J; 2001 Jun; 3(6):451-2. PubMed ID: 11433642 [No Abstract] [Full Text] [Related]
25. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine. Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Thakur CP; Kumar K Indian J Med Res; 1990 Mar; 91():144-8. PubMed ID: 2160914 [TBL] [Abstract][Full Text] [Related]
27. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477 [TBL] [Abstract][Full Text] [Related]
28. Combination of sodium stibogluconate and rifampicin in post kala-azar dermal leishmaniasis. Sharma VK; Prasad HR; Sethuraman G; Khaitan BK Indian J Dermatol Venereol Leprol; 2007; 73(1):53-4. PubMed ID: 17314452 [No Abstract] [Full Text] [Related]
29. Complications of kala azar and its treatment in Kenya. Chunge CN; Gachihi G; Chulay JD; Spencer HC East Afr Med J; 1984 Feb; 61(2):120-7. PubMed ID: 6088210 [No Abstract] [Full Text] [Related]
30. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Musa AM; Khalil EA; Mahgoub FA; Elgawi SH; Modabber F; Elkadaru AE; Aboud MH; Noazin S; Ghalib HW; El-Hassan AM; Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805 [TBL] [Abstract][Full Text] [Related]
31. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033 [TBL] [Abstract][Full Text] [Related]
32. Post-kala-azar dermal leishmaniasis: a clinical and therapeutic study. Ramesh V; Misra RS; Saxena U; Mukherjee A Int J Dermatol; 1993 Apr; 32(4):272-5. PubMed ID: 8387467 [TBL] [Abstract][Full Text] [Related]
33. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone. Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363 [TBL] [Abstract][Full Text] [Related]
34. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Antinori S; Longhi E; Bestetti G; Piolini R; Acquaviva V; Foschi A; Trovati S; Parravicini C; Corbellino M; Meroni L Br J Dermatol; 2007 Nov; 157(5):1032-6. PubMed ID: 17854365 [TBL] [Abstract][Full Text] [Related]
35. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647 [TBL] [Abstract][Full Text] [Related]
36. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Ramesh V; Katara GK; Verma S; Salotra P Br J Dermatol; 2011 Aug; 165(2):411-4. PubMed ID: 21561437 [TBL] [Abstract][Full Text] [Related]
37. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery. Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894 [TBL] [Abstract][Full Text] [Related]
38. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study. Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123 [TBL] [Abstract][Full Text] [Related]
39. Post-kala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient. Ramos A; Cruz I; Muñez E; Salas C; Fernández A; Alvarez-Espejo T Infection; 2008 Mar; 36(2):184-6. PubMed ID: 18327683 [No Abstract] [Full Text] [Related]
40. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Thakur CP; Narain S; Kumar N; Hassan SM; Jha DK; Kumar A Ann Trop Med Parasitol; 1997 Sep; 91(6):611-6. PubMed ID: 9425363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]